A fraction of the nuclear estrogen receptor ␣ (ER␣) is localized to the plasma membrane region of 17␤-estradiol (E2) target cells. We previously reported that ER␣ is a palmitoylated protein. To gain insight into the molecular mechanism of ER␣ residence at the plasma membrane, we tested both the role of palmitoylation and the impact of E2 stimulation on ER␣ membrane localization. The cancer cell lines expressing transfected or endogenous human ER␣ (HeLa and HepG2, respectively) or the ER␣ nonpalmitoylable Cys447Ala mutant transfected in HeLa cells were used as experimental models. We found that palmitoylation of ER␣ enacts ER␣ association with the plasma membrane, interaction with the membrane protein caveolin-1, and nongenomic activities, including activation of signaling pathways and cell proliferation (i.e., ERK and AKT activation, cyclin D 1 promoter activity, DNA synthesis). Moreover, E2 reduces both ER␣ palmitoylation and its interaction with caveolin-1, in a time-and dose-dependent manner. These data point to the physiological role of ER␣ palmitoylation in the receptor localization to the cell membrane and in the regulation of the E2-induced cell proliferation.
INTRODUCTION
The sex steroid 17␤-estradiol (E2) acts by binding to its nuclear receptors (i.e., ER␣ and ER␤) that then transactivate target genes. In addition, E2 induces rapid, nongenomic actions involving plasma membrane-associated signaling that require a membrane ER (Coleman and Smith, 2001; Kelly and Levin, 2001; Jakacka et al., 2002; Marino et al., 2002) . Although different structural and functional properties have been reported for the membrane-associated ER by comparison with nuclear ER␣ and ER␤ (Ropero et al., 2002; Toran-Allerand et al., 2002; Deecher et al., 2003) , immunocytochemical studies revealed the presence of a significant fraction of nuclear ER also on the plasma membrane (Pappas et al., 1995; Norfleet et al., 1999; Dan et al., 2003; Razandi et al., 2003; Arvanitis et al., 2004; Song et al., 2004) . In addition, a single mRNA originates a similarly sized nuclear and membrane ER in ER␣-transfected Chinese hamster ovary and HeLa cells (Razandi et al., 1999; Marino et al., 2002 Marino et al., , 2003 . Thus, ER␣ localizes to both the nucleus and the plasma membrane. Moreover, the membrane ER␣ is emerging as the primary endogenous mediator of E2 rapid responses important in cell proliferation (Marino et al., 1998 (Marino et al., , 2002 Castoria et al., 1999 Castoria et al., , 2001 Razandi et al., 1999 Razandi et al., , 2000 Lobenhofer et al., 2000; Acconcia et al., 2004a; Fernando and Wimalasena, 2004) .
Debate is open regarding the structural bases and the mechanisms for ER␣ maintenance at and translocation to the plasma membrane. ER␣ does not display any intrinsic transmembrane domain (Song et al., 2004) ; thus, ER␣ interaction with specific membrane proteins have been proposed to explain its membrane localization Migliaccio et al., 2002; Razandi et al., 2002 Razandi et al., , 2003 Toran-Allerand et al., 2002; Arvanitis et al., 2004) . In particular, the Ser522 residue has been reported as necessary for ER␣ interaction with caveolin-1. However, the expression of ER␣-Ser522Ala mutant in Chinese hamster ovary cells decreased only 60% of ER␣ on the membrane, extracellular signal-regulated kinase (ERK) activation, and cyclin D 1 gene transcription (Razandi et al., 2003) . Thus, the direct ER␣:caveolin-1 interaction could not be the sole molecular mechanism for ER␣ membrane association. Furthermore, because the protein:protein interaction occurs only after some minutes of E2 stimulation (5-15 min) (Song et al., 2004) , this mechanism does not justify the receptor presence at the plasma membrane of unstimulated target cells reported previously (Pappas et al., 1995; Norfleet et al., 1999; Razandi et al., 1999; Levin, 2001; Dan et al., 2003) . Very recently, we reported that human wild-type ER␣ underwent palmitoyl acyl transferase (PAT)-dependent S-palmitoylation. Moreover, a point mutation of the ER␣-Cys447 residue to Ala completely impaired receptor palmitoylation and the E2-induced rapid activation of the ERK/mitogen-activated protein kinase (MAPK) signaling pathway (Acconcia et al., 2004b) , although this mutant binds E2 with the same affinity than the wild-type ER␣ (Katzenellenbogen et al., Article published online ahead of print. Mol. Biol. Cell 10.1091/ mbc.E04 -07-0547. Article and publication date are available at www.molbiolcell.org/cgi/doi/10.1091/mbc.E04 -07-0547.
1993; Neff et al., 1994) . This observation raises the intriguing hypothesis that the palmitoylation of ER␣ could be the major determinant for ER␣ residence at the plasma membrane.
Here, we examine the role of palmitoylation in localizing ER␣ to the plasma membrane and in promoting the ER␣: caveolin-1 interaction, as well as the role of E2 in regulating ER␣ palmitoylation. Our results indicate that ER␣ palmitoylation is required for ER␣:protein interaction (i.e., caveolin-1) and for the receptor localization to and maintenance at the plasma membrane. As a consequence, ER␣ palmitoylation enables rapid E2 signaling important for cell proliferation.
MATERIALS AND METHODS

Reagents
17␤-Estradiol, gentamicin, penicillin and other antibiotics, GenElute plasmid maxiprep kit, DMEM, RPMI 1640 medium (without phenol red), charcoalstripped fetal calf serum, and the PAT inhibitor 2-bromohexadecanoic acid (2-bromo-palmitate; 2-Br) (IC 50 of ϳ4 M; Varner et al., 2003) were purchased from Sigma-Aldrich (St. Louis, MO). The estrogen receptor inhibitor ICI 182,780 was obtained from Tocris Cookson (Ballwin, MO). 9,10-[ 3 H]Palmitic acid (specific activity 57 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Boston, MA). Methyl-1-[
3 H]thymidine (specific activity 81 Ci/mmol) was purchased from Amersham Biosciences UK (Little Chalfont, Buxkinghamshire, United Kingdom). Lipofectamine reagent was obtained from Invitrogen (Carlsbad, CA). The luciferase kit was obtained from Promega (Madison, WI). Bradford protein assay was obtained from Bio-Rad (Hercules, CA). The monoclonal, anti-phospho-ERK, anti-ER␣ D12 (N terminus), anti-AKT, and anti-␤-actin as well as the polyclonal anti-ERK, anticaveolin-1, and anti-ER␣ MC20 (C terminus) antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The monoclonal anti-ER␣ (fulllength) antibody was purchased from Novocastra (Newcastle, United Kingdom). The polyclonal anti-phospho-AKT antibody was purchased from New England Biolabs (Beverly, MA). CDP-Star, chemiluminescence reagent for Western blot was obtained from PerkinElmer Life and Analytical Sciences (Boston, MA). All the other products were from Sigma-Aldrich. Analytical or reagent grade products, without further purification, were used.
Cell Culture and DNA Synthesis
HepG2 and HeLa cells were routinely grown in 5% CO 2 in modified, phenol red-free RPMI 1640 or DMEM media containing 10% (vol/vol) charcoalstripped fetal calf serum, l-glutamine (2 mM), gentamicin (10 g/ml), and penicillin (100 U/ml). Cells were passaged every 2 d. DNA synthesis was assayed by incubating subconfluent cells (70 -80%) with methyl-1-[
3 H]thymidine (final concentration, 1 Ci/ml). Cells were simultaneously treated with either E2 [final concentration, 10 nM in ethanol/phosphate-buffered saline (PBS) 1:10 (vol/vol)] or vehicle [ethanol/PBS 1:10 (vol/vol) ]. Methyl-1-[ 3 H]thymidine incorporation was assayed 1 h after E2 administration as reported previously (Marino et al., 2001a) . When indicated, the PAT inhibitor 2-Br was added 30 min before E2 administration (final concentration 10 M).
Plasmids
The reporter plasmid pXP2-D 1 -2966-luciferase (pD 1 ), the empty vector (pCMV5), the expression vector pCR3.1-␤-galactosidase, wild-type human ER␣ pSG5-HE0, pSG5-Cys447Ala (human ER␣ point mutant Cys447 residue to Ala), and pKCR2-HE14 (N-terminal deletion mutant of HE0 lacking A/B and DNA binding domains ⌬1-281) have been described previously (Herbert et al., 1994; Marino et al., 2001b Marino et al., , 2002 Acconcia et al., 2004b) . A luciferase dose-response curve showed that the maximum effect was obtained when 1.0 g of plasmids was transfected together with 1.0 g of pCR3.1-␤-galactosidase to normalize for transfection efficiency (ϳ55-65%). Plasmids were purified for transfection using the GenElute plasmid maxiprep kit according to the manufacturer's instructions.
Transfection and Luciferase Assay
HeLa cells were grown to ϳ70% confluence and then transfected using Lipofectamine reagent according to the manufacturer's instructions. Six hours after transfection, the medium was changed, and 24 h after the cells were stimulated with 10 nM E2 for 6 h. The cell lysis procedure as well as the subsequent measurement of luciferase gene expression was performed using the luciferase kit according to the manufacturer's instructions with an PerkinElmer Life and Analytical Sciences (Bad Wildbad, Germany) luminometer. When indicated, the PAT inhibitor 2-Br (final concentration 10 M) was added 30 min before E2 administration.
Cell Labeling with [ 3 H]Palmitate and Immunoprecipitation
Forty-two hours after transfection with either plasmid containing empty, wild-type ER␣ or the ER␣ point mutant, HeLa cells and untransfected HepG2 cells were incubated with 0.5 mCi/ml [ 3 H]palmitate at 37°C for different times ranging between 0 and 240 min. Where indicated, HepG2 and HeLa cells were stimulated with different concentrations of E2 (1, 10, and 100 nM) at different times (10, 60, and 240 min) in the presence of [ 3 H]palmitate. Cells were then washed in ice-cold PBS, harvested by scraping, and lysed in 50 l of lysis buffer [10 mM Tris, pH 7.5, 1 mM EDTA, 0.5 mM EGTA, 10 mM NaCl, 1% (vol/vol) Triton X-100, and 1% (wt/vol) sodium cholate] containing protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride, 1 g/ml leupeptin, and 5 g/ml aprotinin). The cell lysates were then clarified by centrifugation and immunoprecipitated as described previously (Han et al., 2002) . Briefly, equal amounts of soluble cell extracts were incubated with either 2 g of caveolin-1 antibody or different anti-ER␣ antibodies. The optimal signal was obtained using 1 g of anti-ER␣ D12 (N terminus) together with 1 g of either anti-ER␣ AER311 (region 495-595), anti-ER␣ MC20 (C terminus), or anti-ER␣ (full-length ER␣). The lysates and antibodies were incubated for 90 min at 4°C, and then 20 l of protein A-agarose was added for 30 min at 4°C. After centrifugation (50,000 ϫ g for 15 min), the supernatant, and the immunoprecipitated proteins were separated in 7-10% SDS-PAGE. Proteins were electrophoretically transferred to nitrocellulose and then probed overnight at 4°C with anti-caveolin-1 or anti-ER␣ MC20 antibodies. The nitrocellulose was stripped and then probed with anti-caveolin-1 or anti-ER␣ MC20 antibodies. In some experiments, the radioactivity present in immunoprecipitated proteins and in the supernatant was monitored by counting with a Canberra Packard (Milan, Italy) liquid beta-counter.
Confocal Miscroscopy Studies
Wild-type ER␣ or ER␣-Cys447Ala mutant was transiently expressed in HeLa cells grown on coverslips. To visualize only the cytosolic and the plasma membrane distribution of wild-type ER␣ and ER␣-Cys447Ala mutant, HeLa cells were freeze-thawed before fixation in 4% (vol/vol) p-formaldehyde (Mardones and Gonzalez, 2003) and then incubated with MC-20 rabbit polyclonal antibody diluted 1:200 in PBS. After washing, cells were incubated with anti-rabbit fluorescein isothiocyanate-conjugated antibody (Sigma-Aldrich) diluted 1:50 in PBS containing 10 mg/ml bovine serum albumin (BSA). Finally, the slides were mounted in PBS medium containing 80% glycerol and 50 mg/ml 1,4-diazabicyclo[2.2.2]octane (Sigma-Aldrich). Evaluation of antibody specificity was carried out either by omitting the primary antibody or by using nonspecific sera. The confocal imaging was performed on a Radiance 2000 confocal laser scanning microscope (Bio-Rad), equipped with a Nikon 40ϫ, 1.4 numerical aperture objective and with Krypton ion lasers.
Electrophoresis and Immunoblotting
After treatment, cells were lysed and solubilized in 0.125 M Tris, pH 6.8, containing 10% (wt/vol) SDS, 1 mM phenylmethylsulfonyl fluoride, and 5 g/ml leupeptin, and then the cell lysates were boiled for 2 min. Total proteins were quantified using the Bradford protein assay (Bradford, 1976) . Solubilized proteins (20 g) were resolved by 10% SDS-PAGE at 100 V for 1 h at 24°C and then electrophoretically transferred to nitrocellulose for 45 min at 100 V and 4°C. The nitrocellulose was treated with 3% (wt/vol) BSA in 138 mM NaCl, 25 mM Tris, pH 8.0, at 24°C for 1 h and then probed overnight at 4°C with either anti-phospho-ERK or anti-phospho-AKT antibodies. The nitrocellulose was stripped by restore western blot stripping buffer (Pierce Chemical, Rockford, IL) for 10 min at room temperature and then probed with either anti-ERK or anti-AKT and anti-␤-actin antibodies. Antibody reaction was visualized with chemiluminescence Western blotting detection reagent (Amersham Biosciences UK). Where indicated, the PAT inhibitor 2-Br (10 M) was added 30 min before E2 administration.
RESULTS
Palmitoylation Is Required for ER␣ Localization to the Plasma Membrane and Its Interaction with Caveolin-1
We previously demonstrated that ER␣ was a palmitoylated protein and that the ER␣-Cys447 to Ala point mutation impaired palmitoylation of the receptor. This lipid modification was necessary for the induction of nongenomic ERK/ MAPK signal transduction pathway (Acconcia et al., 2004b) . Based on these findings, we postulated that palmitoylation of ER␣ be important for the localization of this receptor to the membrane.
We first verified the occurrence of ER␣ palmitoylation in human cancer cells containing transfected (HeLa) or endogenous (HepG2) receptor. HeLa cells were transiently trans-fected with either an empty vector, a wild-type ER␣-encoding vector or the ER␣ missense mutant in which Cys447 was changed to Ala by site-directed mutagenesis (Acconcia et al., 2004b) , and then incubated with [ 3 H]palmitate for 4 h at 37°C. After ER␣ immunoprecipitation, the radioactivity present in both the immunoprecipitate and the supernatant was determined. As expected, the cell transfected with the empty vector (control) Figure 1a) . ER␣ was not detected in the supernatant fractions (our unpublished data). In addition, the radioactivity present in the palmitoylated caveolin-1 (22-kDa band; Resh, 1999) immunoprecipitated from untransfected HeLa cells was detected as positive control (cav-1) (Figure 1a) . ER␣ palmitoylation was essentially complete within 10 min and remained constant Ͼ240 min (Figure 1b) . No difference in [ 3 H]palmitate incorporation occurred between ER␣-transfected HeLa cells and HepG2 cells (Figure 1b) .
To visualize the cytosolic and/or plasma membrane localization of wild-type and ER␣-Cys447Ala mutant, transfected HeLa cells were studied by immunofluorescence staining (Figure 2, a-c) . By using the anti-ER␣ MC20 antibody, a major population of membrane-associated ER␣ receptor was clearly present in HeLa cells expressing wildtype ER␣, whereas a weak cytosolic staining and no membrane-bound receptor could be detected in HeLa cells expressing the ER␣-Cys447Ala mutant (Figure 2 , compare b with c). Moreover, no ER␣ was detected in HeLa cells that had been transfected with the empty vector (Figure 2a,  control) . We conclude that Cys447 is important for surface membrane localization.
The ability of wild-type ER␣ and of ER␣-Cys447Ala mutant to bind the scaffolding plasma membrane protein caveolin-1 was examined by coimmunoprecipitation of caveolin-1 and ER␣. This was accomplished in HeLa cells transiently transfected with empty, ER␣, or ER␣-Cys447Ala expression vectors. No association between caveolin-1 and ER␣ occurred in cells transfected with the empty vector (control), confirming the lack of any ER isoforms in HeLa cells ( Figure  2, d and e, lane control) . In ER␣-expressing HeLa cells, a 22-kDa band, corresponding to caveolin-1, and a 67-kDa band, corresponding to ER␣, were present (Figure 2, d and e, lane ER␣). On the other hand, ER␣-Cys447Ala mutantexpressing cells failed to interact with caveolin-1 because ER␣ could be immunoprecipitated, but coimmunoprecipitation of caveolin-1 could not be observed (Figure 2, d and e, lane Cys447Ala). These data are consistent with the role of palmitoylation in ER␣ localization to the plasma membrane and in the receptor association with caveolin-1.
ER␣ Palmitoylation Is Negatively Modulated by E2
To assess the ability of E2 to modulate ER␣ palmitoylation, HeLa cells transfected with the ER␣ expression vector and HepG2 cells were incubated with [ 3 H]palmitate for 4 h in the presence of different E2 concentrations. Physiological E2 concentration (10 nM) decreased by half the amount of [ 3 H]palmitate incorporated in wild-type ER␣; similar results were obtained at higher E2 concentrations (i.e., 100 nM), whereas a lower hormone concentration (i.e., 1 nM) was ineffective (our unpublished data). The time course of 10 nM E2 stimulation in cells containing transfected (HeLa) and endogenous (HepG2) ER␣ showed that 60 min of E2 stimulation induced the decrease of [ 3 H]palmitate incorporation ( Figure 3a ) without any change in the protein level ( Figure  3b ). The E2-induced reduction in [ 3 H]palmitate incorporation in both cell lines was completely prevented by pretreating the cells with the ER␣ inhibitor ICI 182,780 (1 M; our unpublished data). In addition to 48% reduction of [ 3 H]palmitate incorporation in ER␣ at 60 min, we found that E2 induced a Ͼ90% reduction in the ability of ER␣ to form a complex with caveolin-1 (Figure 3, c and d) . It is important to note that although E2 reduces palmitoylation of ER␣ and complex formation of ER␣ with caveolin-1, it had no effect on the cellular protein level of either proteins (Figure 3 , c and d). We further asked whether the A/B and C domains of ER␣ contributed in E2-induced down-regulation of both ER␣ palmitoylation and its association to caveolin-1. Surprisingly, from 60 min until 240 min, E2 induced a 40% increase in both receptor palmitoylation (Figure 4a ) and receptor association with caveolin-1 (Figure 4 , b and c) in HeLa cells transfected with ER␣ deletion mutant lacking the A/B and C domains (HE14).
ER␣ Palmitoylation Is Necessary for Nongenomic Activities
In HepG2 cells, the rapid E2-induced activation of both the ERK/MAPK and phosphoinositide-3-kinase (PI3K)/AKT pathways is sufficient and necessary for E2-induced cell cycle progression (i.e., DNA synthesis and transcription of the cyclin D 1 gene) (Marino et al., 2002 (Marino et al., , 2003 . We determined next whether ER␣ palmitoylation could impact on these rapid nongenomic ER␣ activities. E2 induced ERK ( Figure 5 , a and aЈ) and AKT ( Figure 5 , b and bЈ) phosphorylation in ER␣-transfected HeLa and HepG2 cells. If the cells were pretreated with the PAT inhibitor 2-Br, the E2-induced activation of signaling kinases was completely blocked without affecting the basal level of phosphorylation. In agreement with our data mentioned above, E2 was ineffective in inducing ERK and AKT phosphorylation in ER␣-Cys447Ala mutant-transfected HeLa cells. After reprobing the membranes using total ERK and AKT antibodies to recognize the nonphosphorylated forms of these proteins, we found that E2-induced phosphorylation of signaling proteins occurred in the absence of changes in their expression levels.
We have recently demonstrated that the ER-dependent cyclin D 1 transcription and DNA synthesis are some of the downstream targets of E2-induced ERK and AKT activation (Marino et al., 2002 (Marino et al., , 2003 . Accordingly, in ER␣ transfected cells, E2 induced cyclin D 1 promoter activity and [ 3 H]thymidine incorporation into DNA (Figure 6 ). In contrast, neither the cyclin D 1 promoter activity (Figure 6a) nor [ 3 H]thymidine incorporation into DNA (Figure 6b ) was affected by E2 administration to the ER␣-Cys447Ala mutant-transfected cells. In addition, the pretreatment of HeLa cells with the PAT inhibitor 2-Br prevented nongenomic E2-evoked effects ( Figure 6 ). Notably, no changes in cyclin D 1 promoter basal transcription activity and DNA synthesis were detected after the treatment with the PAT inhibitor 2-Br alone. Thus, palmitoylated ER␣ mediates the E2-induced activation of ERK, AKT, cyclin D 1 promoter activity, and DNA synthesis. These findings demonstrate a critical role of palmitoylation in ER␣-mediated cell proliferation. 
DISCUSSION
The mechanism(s) underling the mitogenic role played by E2 in different target tissues is now better understood based on the studies reported by different laboratories, including our own. These studies designate a strict relationship between E2-induced nongenomic functions and cell proliferation (Marino et al., 1998 (Marino et al., , 2001a (Marino et al., ,b, 2002 (Marino et al., , 2003 Castoria et al., 1999 Castoria et al., , 2001 Razandi et al., 1999 Razandi et al., , 2000 Lobenhofer et al., 2000; Acconcia et al., 2004a; Fernando and Wimalasena, 2004) . The activation of ERK/MAPK, PI3K/AKT, and protein kinase C, rapidly generated after E2 binding to ER␣, are all defined as necessary and sufficient for E2-induced cell cycle-regulating genes (e.g., cyclin D 1 ) and the G1-to-S phase progression in different cell lines. These actions are thought to require a plasma membrane ER␣.
The idea that surface membrane ER is identical to the nuclear ER␣ seems now very plausible as deduced by using antibodies raised against multiple epitopes of the nuclear receptor (Pappas et al., 1995; Norfleet et al., 1999; Levin, 2001; Dan et al., 2003) . Moreover, the ER␣ presence on the human cell plasma membrane and the ER␣ role in the cellular effects of E2 are increasingly accepted (Razandi et al., 1999; Simoncini et al., 2000; Kousteni et al., 2001; Wise et al., 2001) .
Despite clear progress, many questions are still unanswered such as the structural bases and the mechanism(s) for ER␣ localization to and maintenance at the plasma membrane. This issue has been addressed in a few papers that indicate that the ER␣ membrane localization could result from receptor interaction with specific membrane proteins and/or lipid modifications Razandi et al., 2002; Li et al., 2003; Acconcia et al., 2004b; Arvanitis et al., 2004) . In particular, in the region of plasma membrane, ER␣ can form a third-party protein (i.e., Shc/ER␣/insulin-like growth factor-1 [IGF-1] receptor) and/or associates in a ternary complex to the membrane tyrosine kinase Src and p85 (the catalytic subunit of PI3K), causing Src/Ras/ERK and PI3K/AKT pathway activation and DNA synthesis (Castoria et al., 2001; Migliaccio et al., 2002; Song et al., 2004) . This association occurs only after some minutes of E2 stimulation (5-15 min), suggesting a recruitment of ER␣ from the cytosol, but does not clarify the receptor presence at the plasma membrane reported in several papers (Pappas et al., 1995; Norfleet et al., 1999; Razandi et al., 1999; Levin, 2001; Dan et al., 2003) . Recently, the Ser522 residue within the E domain of ER␣ has been reported to be critical in linking the receptor to the cell membrane through an interaction with caveolin-1 (Razandi et al., 2003) . However, the expression of ER␣-Ser522Ala mutant in Chinese hamster ovary cells decreased only 60% of ER␣ on the membrane, ERK activation, and cyclin D 1 gene transcription, suggesting that Ser522 is not the sole residue for ER␣ membrane association. We recently identified the ER␣ posttranslational modification with palmitate (Acconcia et al., 2004b) , and here, for the first time, we demonstrate that palmitoylation is a determinant for ER␣ residence at the plasma membrane caveolae. In fact, we prove that ER␣ localization to the membrane is dependent on ER␣ palmitoylation because the unpalmitoylable ER␣-Cys477Ala mutant, which maintains an intact Ser522 residue, is unable to localize to the membrane, to interact with caveolin-1, and to generate the E2-induced rapid membrane-starting signal pathways important in cell proliferation. Thus, present data describe a new model in which Cys447 residue in the E domain of the ER␣ assures the receptor localization to and maintenance at the plasma membrane caveolae. Moreover, the A/B and C domains of ER␣ do not contribute to membrane ER localization; in fact, HE14 ER␣ deletion mutant, which contains only E and F domains, still undergoes to palmitoylation and associates to caveolin-1.
One of the main findings in this study is the time-and concentration-dependent negative regulation of wild-type ER␣ palmitoylation exerted by E2. Because palmitoylation is a rapid reversible chemical modification (Bijlmakers and Marsh, 2003) , it is most likely that the membrane-bound full-length receptor undergoes to the E2-induced depalmitoylation. Moreover, the E2 binding to the soluble, cytosolic, receptor, enacting ER␣ structural modifications (Brzozowski et al., 1997) , could impair the PAT action (i.e., PAT:ER␣ recognition). In fact, it has been reported that the Cys447 residue is not yet able to react with the iodoacetic acid a cysteine-reacting reagent after E2 binding (Hegy et al., 1996) , suggesting that the Cys447 residue could be buried into the protein matrix. In addition, E2 also decreases the ER␣:caveolin-1 complex further sustaining the pivotal role played by palmitoylation in ER␣ membrane localization. On the other hand, the deletion of A/B and C domains of the ER␣ may impair the E2-induced structural modifications of cytosolic ER␣, thus enhancing its palmitoylation (40%). In addition these domains may facilitate the E2-dependent depalmitoylation and dissociation from caveolin-1 of the membrane bound ER␣. As a consequence, the A/B and C domains render both soluble and membrane-bound receptor competent to E2 regulation.
The ER␣ palmitoylation is necessary for E2-induced ERK/ MAPK and PI3K/AKT pathway activation as well as for cyclin D 1 transcription and DNA synthesis as demonstrated by the effect of the PAT inhibitor 2-Br and the nonresponsive behavior of the ER␣-Cys447Ala mutant. The palmitoylation of ER␣ barely influences ER␣ genomic activities (i.e., estrogen responsive element-containing gene transcription) (Acconcia et al., 2004b) . Similar results were obtained in HepG2 cells, which express endogenous ER␣. In fact, ER␣ palmitoylation was detected and regulated by E2 in the HepG2 cell line. Moreover, inhibition of the PAT activity by 2-Br prevents ERK/MAPK and PI3K/AKT activation. Our findings indicate a critical requirement of palmitoylation for the ER␣ plasma membrane localization and the initiation of the nongenomic events important to E2-dependent G1-S phase progression (i.e., cyclin D 1 transcription and DNA synthesis).
In conclusion, palmitoylation enables ER␣ to reside at the plasma membrane and to interact with caveolin-1. On E2 binding, the ER␣ may undergo depalmitoylation and dissociate from caveolin-1. Thus, ER␣ could be relocated by docking to other partner proteins (i.e., Shc/IGF-1 receptor; Src/ p85) (Castoria et al., 2001; Migliaccio et al., 2002; Song et al., 2002 Song et al., , 2004 . As a consequence, the nongenomic signals could be generated (i.e., ERK/MAPK, PI3K/AKT). Thus, a cycle of inactive/active receptor may occur in the proximity of the plasma membrane as reported for the ER␣ nuclear pool (Reid et al., 2003) . In the future, electron microscopic strategies (e.g., double labeling of ER␣ and caveolin-1, association/release of ER␣ from membrane in the presence of E2) will substantiate this action mechanism. However, from now on palmitoylation can be regarded as a physiological regulatory device enabling ER␣ to initiate E2-induced cell proliferation and provides a new potential target in the treatment of E2-related cancers.
